Wave Life Sciences (WVE) director plans 12,700-share sale under 10b5-1

Rhea-AI Filing Summary

Wave Life Sciences, Inc. director Adrian Rawcliffe reported selling 12,700 shares of common stock on August 12, 2026, in an open-market transaction at a reported price of $5.29 per share (weighted average). The sales were effected under a Rule 10b5-1 trading plan adopted on March 6, 2026, and left him with 0 shares of directly held common stock reported in this filing.

Insider Trade Summary 10b5-1

Net Seller: 12,700 shares

Net Sell 1 txn

Insider Rawcliffe Adrian

Role Director

Sold 12,700 shs ($67K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F2	12,700	$5.29	$67K

Holdings After Transaction: Common Stock — 0 shares (Direct)

Footnotes (2)

1. F1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2026.
2. F2. The price reflected is the weighted-average sale price for stock sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $5.16 to $5.42 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

Key Figures

Shares sold: 12,700 shares Weighted-average sale price: $5.29 per share Sale price range: $5.16 to $5.42 per share +3 more

6 metrics

Shares sold 12,700 shares Common stock sold by director on August 12, 2026

Weighted-average sale price $5.29 per share Open-market sale of common stock

Sale price range $5.16 to $5.42 per share Multiple transactions within this price range

Shares held after transaction 0 shares Directly held common stock reported following sale

10b5-1 plan adoption date March 6, 2026 Trading plan governing the reported sales

Redomiciliation date August 7, 2026 U.S. entity became successor to Singapore entity

Key Terms

Rule 10b5-1 trading plan, weighted-average sale price, Redomiciliation

3 terms

Rule 10b5-1 trading plan regulatory

"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted-average sale price financial

"The price reflected is the weighted-average sale price for stock sold."

Redomiciliation regulatory

"The Redomiciliation had the effect of changing Wave-Singapore's domicile"

Redomiciliation is when a company legally changes its country of incorporation while keeping the same business and assets, like moving a house to a new neighborhood but keeping the same furniture. Investors care because the company then follows a different set of laws and tax rules, which can change shareholder rights, reporting standards, dividend treatment and the ease of trading the stock, potentially affecting risk and return.

FAQ

What insider transaction did Wave Life Sciences (WVE) report for Adrian Rawcliffe?

Adrian Rawcliffe, a director of Wave Life Sciences, Inc., reported selling 12,700 shares of common stock on August 12, 2026. The sale was executed in an open-market transaction at a weighted-average price of $5.29 per share.

At what price were the Wave Life Sciences (WVE) shares sold in this Form 4?

The reported sale used a weighted-average price of $5.29 per share. A footnote states the shares were sold in multiple transactions, with prices ranging from $5.16 to $5.42 per share during the reported trading.

How many Wave Life Sciences (WVE) shares does Adrian Rawcliffe hold after this transaction?

Following the reported sale of 12,700 shares, Adrian Rawcliffe is shown with 0 shares of directly held Wave Life Sciences common stock in this Form 4. The filing does not list any remaining non-derivative direct holdings.

Was the Wave Life Sciences (WVE) insider sale under a Rule 10b5-1 plan?

Yes. A footnote states the sales were effected under a Rule 10b5-1 trading plan adopted by Adrian Rawcliffe on March 6, 2026. Such plans pre-arrange trades according to predetermined instructions.

What does the Form 4 say about Wave Life Sciences’ (WVE) redomiciliation?

The remarks explain that on August 7, 2026, Wave Life Sciences, Inc. became the successor to Wave Life Sciences Ltd. via a one-for-one share exchange. The redomiciliation changed the corporate domicile but did not alter proportionate securityholder interests.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/13/2026 - 09:00 PM Accepted by SEC EDGAR 08/13/2026 - 09:00 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Rawcliffe Adrian

(Last) (First) (Middle)

C/O WAVE LIFE SCIENCES, INC.,

733 CONCORD AVE.

(Street)

CAMBRIDGE MASSACHUSETTS 02138

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Wave Life Sciences, Inc. [ WVE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/12/2026		S(1)		12,700	D	$5.29(2)	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2026.

2. The price reflected is the weighted-average sale price for stock sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $5.16 to $5.42 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

Remarks:

On August 7, 2026, Wave Life Sciences, Inc., a Delaware corporation, became the successor of Wave Life Sciences Ltd., a company organized under the laws of the Republic of Singapore ("Wave-Singapore"), pursuant to a scheme of arrangement under Singapore law under which all issued ordinary shares in the capital of Wave-Singapore were exchanged on a one-for-one basis for shares of common stock of Wave Life Sciences, Inc. (the "Redomiciliation"). The Redomiciliation had the effect of changing Wave-Singapore's domicile, but did not alter the proportionate interests of securityholders. Exhibit 24.1 - Power of Attorney

	/s/ Adrian Rawcliffe	08/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)